U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO[R] (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease OSAKA, Japan [...]